NASDAQ: BBIOBridgebio Pharma Inc Stock Ownership - Who owns Bridgebio Pharma?
Insider buying vs selling
Have Bridgebio Pharma Inc insiders been buying or selling?
Buy
Sell
| Name | Role | Date | Shares | Price | Value |
|---|---|---|---|---|---|
| Andrea Ellis | Director | 2025-04-14 | 10,000 | $8.45 | $84.50kBuy |
| Andrea Ellis | Director | 2025-04-14 | 10,000 | $35.00 | $350.00kSell |
| Andrea Ellis | Director | 2025-04-01 | 30,000 | $8.45 | $253.50kBuy |
| Andrea Ellis | Director | 2025-04-01 | 30,000 | $34.05 | $1.02MSell |
| Neil Kumar | Chief Executive Officer | 2025-03-25 | 75,000 | $36.87 | $2.76MSell |
| Hannah Valantine | Director | 2025-03-06 | 12,875 | $32.58 | $419.51kSell |
| Hannah Valantine | Director | 2025-03-06 | 12,875 | $16.75 | $215.66kBuy |
| Kkr Genetic Disorder LP | 10% Owner | 2025-03-05 | 6,000,000 | $32.96 | $197.76MSell |
| Neil Kumar | Chief Executive Officer | 2025-02-25 | 37,899 | $33.36 | $1.26MSell |
| Brian C. Stephenson | CFO and Treasurer | 2025-02-25 | 100 | $34.18 | $3.42kSell |
BBIO insiders have sold more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership
Be the first to know when BBIO insiders and whales buy or sell their stock.
BBIO Shareholders
What type of owners hold Bridgebio Pharma Inc stock?
Institutional
Insider
Retail
| Name | Hold | Shares | Value | Type |
|---|---|---|---|---|
| Kkr Group Partnership LP | 19.40% | 36,900,661 | $1.25B | Insider |
| Viking Global Performance LLC | 14.00% | 26,620,991 | $901.65M | Insider |
| Kohlberg Kravis Roberts Co LP | 13.28% | 25,260,971 | $855.59M | Institution |
| Viking Global Investors LP | 13.21% | 25,120,991 | $850.85M | Institution |
| Viking Global Investors LP | 11.60% | 22,055,375 | $747.02M | Insider |
| Kkr Genetic Disorder LP | 10.13% | 19,260,971 | $652.37M | Insider |
| Vanguard Group Inc | 7.93% | 15,077,915 | $510.69M | Institution |
| Blackrock Inc | 7.21% | 13,709,646 | $464.35M | Institution |
| Neil Kumar | 4.28% | 8,147,223 | $275.95M | Insider |
| State Street Corp | 3.25% | 6,182,627 | $209.41M | Institution |
BBIO vs Biotech Stocks
Bridgebio Pharma Stock Ownership FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.